Targeted molecular iron oxide contrast agents for imaging atherosclerotic plaque

Evans, Rhiannon; Lavín Plaza, Begoña; Phinikaridou, Alkystis; Chooi, Kok Yean; Mohri, Zahra; Wong, Eunice; Boyle, Joseph; Krams, Rob; Botnar, René; Long, Nicholas

Targeted molecular iron oxide contrast agents for imaging atherosclerotic plaque

Download

Targeted_molecular_iron_oxide_contrast_agents.pdf (1.93 MB)

Official URL

https://doi.org/10.7150/ntno.44712

Publication date

2020

Authors

Evans, Rhiannon

Lavín Plaza, Begoña

Phinikaridou, Alkystis

Publisher

IvySpring

Citations

Exportar

URI

https://hdl.handle.net/20.500.14352/97000

Citation

Evans RJ, Lavin B, Phinikaridou A, Chooi KY, Mohri Z, Wong E, Boyle JJ, Krams R, Botnar R, Long NJ. Targeted Molecular Iron Oxide Contrast Agents for Imaging Atherosclerotic Plaque. Nanotheranostics 2020; 4(4):184-194. doi:10.7150/ntno.44712. https://www.ntno.org/v04p0184.htm

Abstract

Cardiovascular disease remains a leading cause of death worldwide, with vulnerable plaque rupture the underlying cause of many heart attacks and strokes. Much research is focused on identifying an imaging biomarker to differentiate stable and vulnerable plaque. Magnetic Resonance Imaging (MRI) is a non-ionising and non-invasive imaging modality with excellent soft tissue contrast. However, MRI has relatively low sensitivity (micromolar) for contrast agent detection compared to nuclear imaging techniques. There is also an increasing emphasis on developing MRI probes that are not based on gadolinium chelates because of increasing concerns over associated systemic toxicity and deposits1. To address the sensitivity and safety concerns of gadolinium this project focused on the development of a high relaxivity probe based on superparamagnetic iron oxide nanoparticles for the imaging of atherosclerotic plaque with MRI. With development, this may facilitate differentiating stable and vulnerable plaque in vivo.